🚀 VC round data is live in beta, check it out!
Aclaris Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aclaris Therapeutics and similar public comparables like Cybin, Adlai Nortye, Foghorn Therapeutics, Binex and more.
Aclaris Therapeutics Overview
About Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Founded
2012
HQ
Employees
64
Website
Sectors
Financials (LTM)
EV
$235M
Aclaris Therapeutics Financials
Aclaris Therapeutics reported last 12-month revenue of $7M.
In the same LTM period, Aclaris Therapeutics generated $6M in gross profit and had net loss of ($68M).
Revenue (LTM)
Aclaris Therapeutics P&L
In the most recent fiscal year, Aclaris Therapeutics reported revenue of $8M and EBITDA of ($70M).
Aclaris Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7M | XXX | $8M | XXX | XXX | XXX |
| Gross Profit | $6M | XXX | $542K | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 7% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($70M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (892%) | XXX | XXX | XXX |
| EBIT Margin | (1088%) | XXX | (898%) | XXX | XXX | XXX |
| Net Profit | ($68M) | XXX | ($65M) | XXX | XXX | XXX |
| Net Margin | (954%) | XXX | (830%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aclaris Therapeutics Stock Performance
Aclaris Therapeutics has current market cap of $331M, and enterprise value of $235M.
Market Cap Evolution
Aclaris Therapeutics' stock price is $3.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $235M | $331M | 0.0% | XXX | XXX | XXX | $-0.60 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAclaris Therapeutics Valuation Multiples
Aclaris Therapeutics trades at 33.0x EV/Revenue multiple, and (3.4x) EV/EBITDA.
EV / Revenue (LTM)
Aclaris Therapeutics Financial Valuation Multiples
As of March 18, 2026, Aclaris Therapeutics has market cap of $331M and EV of $235M.
Equity research analysts estimate Aclaris Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aclaris Therapeutics has a P/E ratio of (4.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $331M | XXX | $331M | XXX | XXX | XXX |
| EV (current) | $235M | XXX | $235M | XXX | XXX | XXX |
| EV/Revenue | 33.0x | XXX | 30.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.4x) | XXX | XXX | XXX |
| EV/EBIT | (3.0x) | XXX | (3.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 41.3x | XXX | 433.7x | XXX | XXX | XXX |
| P/E | (4.9x) | XXX | (5.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aclaris Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aclaris Therapeutics Margins & Growth Rates
Aclaris Therapeutics' revenue in the last 12 month declined by (34%).
Aclaris Therapeutics' revenue per employee in the last FY averaged $0.1M.
Aclaris Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (34%) | XXX | (42%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (892%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 314% | XXX | 281% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 782% | XXX | 673% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 905% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aclaris Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cybin | XXX | XXX | XXX | XXX | XXX | XXX |
| Adlai Nortye | XXX | XXX | XXX | XXX | XXX | XXX |
| Foghorn Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Binex | XXX | XXX | XXX | XXX | XXX | XXX |
| XOMA Royalty | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aclaris Therapeutics M&A Activity
Aclaris Therapeutics acquired XXX companies to date.
Last acquisition by Aclaris Therapeutics was on XXXXXXXX, XXXXX. Aclaris Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aclaris Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAclaris Therapeutics Investment Activity
Aclaris Therapeutics invested in XXX companies to date.
Aclaris Therapeutics made its latest investment on XXXXXXXX, XXXXX. Aclaris Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aclaris Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aclaris Therapeutics
| When was Aclaris Therapeutics founded? | Aclaris Therapeutics was founded in 2012. |
| Where is Aclaris Therapeutics headquartered? | Aclaris Therapeutics is headquartered in United States. |
| How many employees does Aclaris Therapeutics have? | As of today, Aclaris Therapeutics has over 64 employees. |
| Who is the CEO of Aclaris Therapeutics? | Aclaris Therapeutics' CEO is Neal Walker. |
| Is Aclaris Therapeutics publicly listed? | Yes, Aclaris Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Aclaris Therapeutics? | Aclaris Therapeutics trades under ACRS ticker. |
| When did Aclaris Therapeutics go public? | Aclaris Therapeutics went public in 2015. |
| Who are competitors of Aclaris Therapeutics? | Aclaris Therapeutics main competitors are Cybin, Adlai Nortye, Foghorn Therapeutics, Binex. |
| What is the current market cap of Aclaris Therapeutics? | Aclaris Therapeutics' current market cap is $331M. |
| What is the current revenue of Aclaris Therapeutics? | Aclaris Therapeutics' last 12 months revenue is $7M. |
| What is the current revenue growth of Aclaris Therapeutics? | Aclaris Therapeutics revenue growth (NTM/LTM) is (34%). |
| What is the current EV/Revenue multiple of Aclaris Therapeutics? | Current revenue multiple of Aclaris Therapeutics is 33.0x. |
| Is Aclaris Therapeutics profitable? | No, Aclaris Therapeutics is not profitable. |
| What is the current net income of Aclaris Therapeutics? | Aclaris Therapeutics' last 12 months net income is ($68M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.